Navigation Links
DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI, FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioPharma, Inc. (OTCBB: http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB) ("DOR" or the "Company") announced today that the European Patent Office has granted a patent, EP 1024827 B1, with claims related to oral vaccination using mutated non-toxic forms of botulinum neurotoxin as a vaccine to prevent exposure to botulinum toxin. The European patent follows the issuance of a patent in the United States, U.S. 6,051,239, which was granted in April, 2000 and contains equivalent claims for oral vaccination. DOR has exclusively licensed these issued patents and related patent applications from Thomas Jefferson University.

Both the newly issued European patent and the formerly issued United States patent stem from the work of Dr. Lance Simpson at Thomas Jefferson University demonstrating that mutated forms of botulinum toxin can be administered orally to induce protective immunity to natural toxin exposure. The claims in the granted European patent provide protection for the use of certain non-toxic mutants of botulinum toxin that are capable of translocation from the gut to the general circulation for preparation of an oral vaccine.

"The grant of the European patent describing the underlying technology is an additional milestone that reinforces our patent portfolio in botulinum vaccines," said Christopher J. Schaber, PhD, President and CEO of DOR. "We also have applications in both the US and other key jurisdictions that cover additional features of BT-VACC™. We believe that oral vaccination will provide advantages over injectable botulinum vaccines because of ease of administration and rapid distribution which can facilitate mass inoculations in time of need. We hope to
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:5/22/2013)... Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a ... Sankyo), announced on May 22 the actions that ... past conduct under prior management ... continues to support Ranbaxy in its efforts to ... which led to the investigations by the U.S. ...
(Date:5/22/2013)... Israel , May 22, 2013  Rosetta ... developer and provider of microRNA-based molecular diagnostics, announces that ... Chief Executive Officer of Rosetta Genomics, will deliver a ... place from June 3-6, 2013 in New York City.  ... 4 th at 2:00 p.m. Eastern time. ...
(Date:5/22/2013)... 22, 2013  BD (Becton, Dickinson and Company) (NYSE: ... company, announced today the publication of its 2012 ... and it continues to focus on the Company,s shared ... the principles of shared value — creating value for ... societies — are fundamental to our strategy," said ...
Breaking Medicine Technology:Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3
... , , SAN DIEGO, Sept. ... a leader in adult stem cell research and manufacturing, announced today ... California,s Food & Drug Branch to manufacture stem cells for human ... with California law and the applicable provisions of the Code of ...
... Conn., Aug 31 The results of the initial clinical trial ... for varicose veins, will be delivered on Wednesday, September 2, at ... Monaco. The device combines mechanical and chemical modalities to accomplish vein ... is Steve Elias MD FACS FACPh, Associate Professor of Surgery at ...
Cached Medicine Technology:Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells 2ClariVein(TM) Catheter for Varicose Veins: Clinical Trial Results to be Presented 2
(Date:5/22/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- ... of suffering, but new research indicates the combination of ... -- a smaller brain. , , Already aware that ... scientists wanted to determine if having both conditions together ... about 2 percent -- isn,t alarming, study authors said, ...
(Date:5/22/2013)... Phelps Memorial Hospital Center in ... Nodule Center for individuals who would like to be ... cancer is the deadliest form of cancer for both men ... die from lung cancer than from breast, colon and prostate ... increases survival rates. It is well established that routine ...
(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science Nathalie ... a recipe for making energy bars at home. , The ... takes a recipe modified from one recently featured on ... it gets more and more difficult to understand what ingredients ... of the nutrition label continues to grow and consumers are ...
(Date:5/22/2013)... HR Strategies recently participated in the Gwinnett ... Fairgrounds, on Friday May 10, 2013. For never having ... raising over $6,300 for cancer research. , HR ... the first $3,000 for Bronze Level Sponsorship. HR Strategies ... to match the company’s contribution of $3,000; and after ...
(Date:5/22/2013)... Go Classy the Original Nudist Travel ... of their newest website http://www.Desire-Mexico.com . The seductively ... Desire Resorts have become the premier Nudist and Lifestyle ... total liberation while allowing you to enjoy a deluxe ... Classy Tours / Caribbean-Hideaways. He goes on to say ...
Breaking Medicine News(10 mins):Health News:Having Both Migraines, Depression May Mean Smaller Brain 2Health News:Having Both Migraines, Depression May Mean Smaller Brain 3Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2
... could soon be offered better treatment thanks to a new ... The University of Nottingham. A purpose-built MRI research ... diseases. The unit is based at the Queens Medical Centre ... of patients using a new, specifically-adapted MRI scanner. ...
... may yield insight into therapies for people, researchers say ... with cancer could provide crucial insight into the human ... and screening for tumors, researchers from the U.S. National ... findings appear in the Oct. 13 online journal ...
... REDONDO BEACH, Calif., Oct. 13 Function Drinks announced ... signed onto the faculty of the Hospital for Special ... as a clinical instructor and attending in spinal surgery. ... research and development for Function Drinks, a line of ...
... SPRING, Texas, Oct. 13 Go Healthy, Inc. (Pink Sheets: ... agreement with Hydro Enterprises, Inc., and Planet Green Solutions, Inc., ... that produces water from any source at a 9.5 pH ... , The ability to place the machines in bottling plants ...
... Oct. 13 Interleukin Genetics, Inc. (NYSE Amex: ILI ) ... of obesity and osteoporosis at medical meetings later this month. The ... and Nutrition Conference & Expo in Denver, Colo. , ... World Diabetes Congress - Montreal, Canada . , Date: ...
... Berger, Managing Member and Founder of Omni Management ... new office in Midtown Manhattan, located at 1120 Avenue of ... strategic geographic expansion," said Berger, "because it just makes good ... , Omni Management Group, LLC ...
Cached Medicine News:Health News:A new scan for lung diseases 2Health News:Dogs Helping to Advance Cancer Research 2Health News:Function Drinks' President & Co-Founder, Dr. Alex Hughes, Joins the Faculty of Cornell's Hospital for Special Surgery 2Health News:Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water 2Health News:Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water 3Health News:Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings 2Health News:Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings 3Health News:Omni Management Group Announces Opening of New York Office 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: